Chemed Corporation heads into mid-May with a notable divergence: the stock has recovered 9% over the past month to $419.65, yet the CEO has been a consistent seller throughout the rally — and now short interest has jumped sharply in the past week.
The insider angle is hard to ignore. CEO Kevin McNamara sold 2,000 shares on May 1 at $421.13, collecting $842,260. That followed two earlier sales in March — 1,500 shares at $369.37 and another 2,000 at $403.18. Together, McNamara has sold 5,500 shares since early March for roughly $2.2 million in total proceeds. The 90-day net insider figure reflects this consistent selling pattern. None of the recent transactions carry high significance scores, suggesting these may be part of a planned programme, but the cadence — three sales in ten weeks across a rising price — is worth noting.
Short interest tells a complementary story. The estimated short position jumped roughly 30% in a single week, from around 376,000 shares to 506,000, pushing SI as a percentage of free float from below 2.7% to 3.6%. That is a meaningful spike, though in absolute terms the position remains modest. Cost to borrow is extremely cheap at just 0.40% annualised — down nearly 50% over the past month — and availability is very loose, meaning there is no friction in the lending market. Short sellers can build positions easily. The borrow market at this level does not signal a squeeze; it signals comfortable, low-cost entry for anyone with a bearish view.
Options positioning reinforces the bullish lean that has emerged over recent weeks. The put/call ratio is running at 0.15 — well below its 20-day average of 0.23 — indicating that calls heavily dominate open options activity. A year ago, the PCR briefly reached 7.5; the contrast with today's 0.15 reading captures just how thoroughly the hedging demand from early spring has dissolved. The ORTEX short score is a modest 33.9 out of 100, placing this name in the lower half of the short-squeeze risk spectrum despite the recent SI increase. Availability is ample, and days-to-cover remain near 0.5 — there is no pressure building from that direction.
The Street sits somewhere between cautious and constructive. The most recent analyst action, from RBC Capital on April 27, raised the target to $436 while maintaining a Sector Perform rating — a mild positive after the same analyst downgraded the stock from Outperform in late February and slashed the prior target from $572 to $422. The consensus mean target is around $446, implying roughly 6% upside from current levels. That is not compelling, but it is not pessimistic either. The bear case centres on Roto-Rooter margin pressure — a 520 basis-point EBITDA margin decline was cited — and softening lead generation. The bull case leans on the VITAS hospice segment, the leading national provider, with demand demographics and a projected 2026 rebound underpinning the long case. At 16.6x trailing earnings and 10.9x EV/EBITDA, valuations are undemanding for a defensive health services franchise, and the dividend score ranks in the 99th percentile.
On the peer comparison, CHE has been a notable laggard this week. DVA gained nearly 30% on the week and CVS jumped almost 20%, while PNTG and CNC each rose 14%. Chemed's modest 2% weekly decline stands in sharp contrast to those moves, suggesting the Q1 earnings beat — the stock jumped over 10% on April 24 — may have already fully absorbed the positive news, leaving it without a fresh catalyst as peers chase sector-wide tailwinds.
With Q2 results not due until July 29, the next six weeks are largely a watching period. The question is whether the short-interest build continues at a pace that finally makes the borrow market tighter, or whether the stock's lagging performance relative to peers attracts renewed buying that absorbs the new short positions before they accumulate further.
See the live data behind this article on ORTEX.
Open CHE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
